Algorics and ADAMAS Announce Strategic Partnership and Release Platform
Houston, TX, USA, June 12, 2017. Algorics, a provider of clinical analytics solutions and software for the global life sciences industry, announced a partnership with life sciences Quality Assurance Consultants, ADAMAS. Under the partnership ADAMAS will make available to clients their comprehensive proprietary audit metrics data via the Acuity platform.
In announcing the partnership, Algorics Chief Commercial Officer Rob Nichols said “There is an increasing requirement of the bio-pharma industry to better understand, and extract value from, the huge volume and variety of increasingly complex data being collected during business as normal. We are delighted that ADAMAS is now able to provide a comprehensive view of data collected from audits allowing their clients to benchmark the quality of their studies against anonymized competitors, thus allowing them to improve the strategic focus of their QA activities.”
Dr. Patricia Fitzgerald, ADAMAS Chief Executive Officer stated “Provision of the audit metrics and benchmarking data to our clients, is just one example of the ADAMAS ethos for informing our clients decisions, allowing them to achieve the best outcomes when considering their clinical quality assurance strategy.”
Algorics and ADAMAS will be demonstrating how Acuity is helping drive next generation auditing at the DIA 2017 Annual Meeting in Chicago, IL from June 18-22 where you can join them at booth 1352.
About
Algorics brings together a team of highly experienced software and life sciences professionals, united behind a single goal: to provide innovative risk based monitoring and clinical analytics solutions and software to the global life sciences industry with consistent and reliable quality. For more information about Algorics and Acuity visit: www.algorics.com
ADAMAS was established in 1997 to provide independent quality assurance, quality management, and training to the healthcare industry. ADAMAS is one of the largest QA consultancy organizations in the world and is well respected within the healthcare industry. We understand our clients’ needs and strive to provide cost-effective services of the highest value. With a diverse set of QA capabilities, ADAMAS is capable of managing both small and large complex QA projects. For more information about ADAMAS visit: www.adamasconsulting.com
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Landmark Phase III Trial Shows Keytruda Significantly Improves Event-Free Survival in LA-HNSCC
April 28th 2025Interim KEYNOTE-689 trial data show that perioperative Keytruda significantly lowers the risk of disease progression or recurrence in resectable, locally advanced head and neck squamous cell carcinoma, marking the first major clinical advance for this patient population in more than two decades.
